Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia
NCT05157971Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Mar 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in acute lymphoblastic leukemia (ALL), sponsored by City of Hope. Primary endpoints: Incidence of adverse events and Dose limiting toxicity. Started Mar 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05157971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157971.